texte alternatif texte alternatif

Vice President & Therapeutic Strategy Leader

Barbara S. Gillespie, MD, MMS, FASN

Barbara S. Gillespie, MD, MMS, FASN

  • Vice President & Therapeutic Strategy Leader at Fortrea, Board Certified Nephrologist, Adjunct Professor at University of North Carolina, Division of Nephrology & Hypertension and past Associate Medical Director at local dialysis units

  • Board of Directors (2018-2023) for the Kidney Health Initiative (a public-private collaboration between the FDA and the American Society of Nephrology). Co-chair of Steering Committee for APOL1 Kidney Disease; work group member (and publication co-author) for Endpoints in IgAN, FSGS, C3G, Peds IgAN and CVO Trial challenges in CKD patients. 

  • Steering Committee for NFK CKD Patient Registry (Patient Network) and serves on multiple Advisory Boards and Stakeholder Committees (e.g., NephCure and International Society of Glomerular Disease’s PARASOL for FSGS Endpoints; PREPARE-NS for PROs; NKF Scientific Workshops for Renal Endpoints in Early CKD; Medical Ad Board for Regional NKF, NephCure MN Consensus Group, PCORI, SONG) and invited faculty speaker at many global nephrology conferences

  • Collaborating with sponsors since 2006 on renal clinical development programs across 20+ indications in both CKD and End Stage Kidney Disease and associated complications